SPECIAL BULLETIN COVID-19 #185 & #186 Now Available

SPECIAL BULLETIN COVID-19 #185: Casirivimab and Imdevimab, for Intravenous Infusion or Subcutaneous Injection

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved products casirivimab and imdevimab to be administered together for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. This Special Bulletin updates SPECIAL BULLETIN COVID-19 #177: Casirivimab and Imdevimab Approved for Emergency Use. Details

SPECIAL BULLETIN COVID-19 #186: Booster Dose of Pfizer-BioNTech COVID-19 Vaccine

This article provides guidance related to the Centers for Disease Control and Prevention (CDC)'s latest recommendations for Pfizer-BioNTech COVID-19 Vaccine booster shots. Beginning Sept. 24, 2021, NC Medicaid vaccine providers may begin administering the booster dose of mRNA COVID-19 vaccine to those beneficiaries who qualify by self-attestation. More information

Providers are encouraged to review this information. All bulletin articles, including those related to COVID-19, are available on DHB's Medicaid Bulletin webpage.